Potential conflicts of interest. R. L. G. reports participation on advisory boards and/or consulting fees from AbbVie, AstraZeneca, Eli Lilly, Gilead Sciences, GSK Pharmaceuticals, and Roche, honoraria for lectures from Gilead Sciences and Pfizer (the latter unrelated to infectious diseases), travel support from Gilead Sciences, de minimis investment in AbCellera, a gift-in-kind to his institution from Gilead Sciences to facilitate an unrelated academic-sponsored clinical trial (NCT03383419), and grants or contracts to his institution from Regeneron and Roivant Sciences (Kinevant Sciences). A. K. reports federal grants from the National Institutes of Health Adaptive COVID-19 Treatment Trial. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.